Rheological and Anticoagulant Therapy of Patients with Chronic Peripheral Occlusive Arterial Disease (COAD)

Deutschinoff, A.; Grozdinsky, L.
May 1987
Angiology;May1987, Vol. 38 Issue 5, p351
Academic Journal
In the course of a six-month study, a three-subgroup cohort of 113 patients (103 m, 10 f, mean age 58±8 years) with angiographically proven occlusive peripheral arterial disease (COAD) Fontaine stage II was analyzed regarding the therapeutic (improvement of walking performance) and prophylactic (prevention of new vascular events) effects of oral treatment with three different drug regimens. Group A (38 patients) was treated with the anticoagulants phenprocoumon or acenocoumarol; group B (32 patients), with the same anticoagulants plus pentoxifylline—800–1200 mg per day; and group C (43 patients) received irregular treatment with various vasodilators, such as xanthinolnicoti- nate, naftidrofuryl, pyridylmethanol, and others. At the end of the trial period a significant increase in systolic ankle pressure index and walking distance was observed in group B whereas the two other groups showed minor changes only. The elevated plasma fibrinogen concentration in group B was also significantly decreased. The percentage of atherosclerotic complications such as new arterial thrombosis in the lower limbs, newly appeared stenocardia, myocardial infarction, transient ischemic attack (TIA), and stroke was highest in group C (20%), relatively lower in group A (10%), and lowest In group B (3%). The percentage of hemorrhagic complications was minimal, with no significant differences between group A and group B. These complications were mild and disappeared quickly. The combined therapy with anticoagulants and pentoxifylline had a marked therapeutic and probably prophylactic effect as regards thromboembolic complications in patients with COAD and other localizations of atherosclerosis.


Related Articles

  • PERIPHERAL ARTERIAL EMBOLISM. Haimovici, Henry // Angiology;Feb1950, Vol. 1 Issue 1, p20 

    The article cites several studies related to peripheral arterial embolism. Ever since 1911, when the first successful embolectomy was performed, there has been a steadily growing literature on peripheral arterial embolism. From then until 1934, embolectomy was considered the only weapon against...

  • Pulmonary embolism: identification, clinical features and management.  // Nursing Standard;3/18/2009, Vol. 23 Issue 28, p49 

    The article discusses pulmonary embolism, its identification, pathophysiology, diagnosis, and management. The signs and symptoms of pulmonary embolism and deep vein thrombosis, which can give rise to pulmonary embolism, are listed. A table of risk factors for the development of pulmonary...

  • Is There a Role for Oral Anticoagulant Therapy in Patients with Peripheral Arterial Disease? Cosmi, B.; Palareti, G. // Current Drug Targets - Cardiovascular & Haematological Disorders;Sep2004, Vol. 4 Issue 3, p269 

    Peripheral arterial disease (PAD) is an index of systemic atherosclerotic disease and is associated with a high incidence of atherothrombotic complications in coronary, cerebral and peripheral arteries. While antiplatelet agents have been extensively evaluated and shown to be effective in...

  • LONG-TERM DAILY OUTPATIENT HEPARIN THERAPY IN HYPERLIPEMIC AND NORMOLIPEMIC ATHEROSCLEROTIC STATES. Woldow, Asher; Goldberg, Harry; Gratz, Margaret // Angiology;Mar1970, Vol. 21 Issue 3, p180 

    1. It is confirmed that heparin given as a single dose is followed by a rebound lipemia. However, when given in multiple doses at 4-hr, intervals the rebound can be prevented and prolonged clearing accomplished. This was noted in patients confined to hospitals and reported previously. Multiple...


    Focuses on the capability of sublingual heparin in restoring the distribution of lipoprotein in the body in the treatment of atherosclerosis. Cause of atherosclerosis; Importance of the clearing factor of the heparin in its capacity in treating atherosclerosis; Developments in the heparin therapy.

  • A MEDICAL APPRAISAL OF THERAPY FOR OCCLUSIVE ARTERIAL DISEASE. Stein, Irwin D. // Angiology;Apr1964, Vol. 15 Issue 4, p188 

    In treating occlusive arterial disease of the limbs one must nevertheless consider the whole patient. We have tubular vision when we limit ourselves to a particular drug or surgical measure. At best we still are a long way from the ideal method of management, which is prevention. This may have...

  • SPEED OF ANTICOAGULATION IN DVT. Douglas, Montgomery; Strelnick, Alvin // Journal of Family Practice;Mar1998, Vol. 46 Issue 3, p202 

    This article focuses on a study related to the speed of anticoagulation in deep vein thrombosis (DVT). In 1986, the researchers of the current study reported that DVT patients who failed to achieve the lower limit of activated partial thromboplastin time within the first 24 hours after receiving...

  • Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and anti-phospholipid syndrome. Chang, P.-C.; Chen, W.-S.; Lin, H.-Y.; Lee, H.-M.; Chen, S.-J. // Lupus;Feb2010, Vol. 19 Issue 2, p206 

    Combined central retinal artery occlusion and central retinal venous occlusion have been rarely reported in patients with systemic lupus erythematosus and anti-phospholipid syndrome. The impact of this severe vaso-occlusive disease on vision is usually devastating and permanent in spite of...

  • The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective. Cleanthis, M.; Flather, Marcus // Clinical Risk;May2009, Vol. 15 Issue 3, p106 

    The article comments on the dangers of discontinuing the use of anti-platelets like clopidogrel. According to the author, anti-platelets increase bleeding risk, but they also cut the risk of arterial occlusion in the cerebral and cardiac vasculature. It is stated that bleeding risk would lead to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics